Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 4/20 | 0.86 |
| ▸ | TSHR | P16473 | 3/20 | 0.86 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.86 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.86 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.86 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.86 |
| ▸ | TTR | P02766 | 1/20 | 0.86 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.86 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.86 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.86 |
| ▸ | PPARG | P37231 | 1/20 | 0.86 |
| ▸ | HTR2B | P41595 | 1/20 | 0.86 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.86 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.86 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.86 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.51 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gemfibrozil SCHEMBL1880616 | 0.93 | PPARA (1.00) | PPARATSHRCYP2C9CYP2C8SMN1; SMN2 | |
| Gemfibrozil SCHEMBL29398115 | 0.93 | PPARA (1.00) | PPARATSHRCYP2C9CYP2C8SMN1; SMN2 | |
| Gemfibrozil SCHEMBL4813 | 0.93 | PPARA (1.00) | PPARATSHRCYP2C9CYP2C8SMN1; SMN2 | |
| Gemfibrozil SCHEMBL20770039 | 0.93 | PPARA (1.00) | PPARATSHRCYP2C9CYP2C8SMN1; SMN2 | |
| Gemfibrozil SCHEMBL10542601 | 0.91 | PPARA (0.97) | PPARATSHRCYP2C9CYP2C8SMN1; SMN2 | |
| Gemfibrozil SCHEMBL21052128 | 0.91 | PPARA (0.97) | PPARATSHRCYP2C9CYP2C8SMN1; SMN2 | |
| Gemfibrozil SCHEMBL457931 | 0.91 | PPARA (0.97) | PPARATSHRCYP2C9CYP2C8SMN1; SMN2 | |
| Gemfibrozil SCHEMBL6033508 | 0.88 | PPARA (0.90) | PPARATSHRCYP2C9CYP2C8SMN1; SMN2 | |
| SCHEMBL21991936 | 0.85 | PPARA (0.64) | PPARATSHRCYP2C9CYP2C8SMN1; SMN2 | |
| SCHEMBL21991307 | 0.84 | CYP2C9 (1.00) | PPARATSHRCYP2C9CYP2C8SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023174941-A1 | FIBRATE COMPOSITIONS FOR TREATING INFLAMMATION AND NEUROINFLAMMATION | TRx Biosciences Limited (GB) | 2023-09-21 | — | — | WO | disclosed |
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885TSHR 3214/4885CYP2C9 1183/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | PPARA 806/4885TSHR 3214/4885CYP2C9 1183/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885TSHR 3214/4885CYP2C9 1183/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885TSHR 3214/4885CYP2C9 1183/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885TSHR 3214/4885CYP2C9 1183/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885TSHR 3214/4885CYP2C9 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.